NASDAQ · OTLK
Outlook Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for OTLK: Dec 18, 2026
Outlook Therapeutics, Inc. Common Stock is estimated to report earnings on 12/18/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.08. The reported EPS for the same quarter last year was $-0.22.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.08 | $-0.07 | $-0.08 | 2 |
| Dec 2026 | $-0.06 | $-0.05 | $-0.08 | 2 |
| Mar 2027 | $-0.05 | $-0.03 | $-0.07 | 2 |
| Jun 2027 | $-0.04 | $-0.03 | $-0.06 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · BNK Invest · Zacks · MarketBeat- RTTNews · Oct 9, 1:27 PM EDTOutlook Therapeutics Names Greg DiPasquale Chief Commercial Officer(RTTNews) – On Friday, Outlook Therapeutics (OTLK), a biopharmaceutical company developing and commercializing LYTENAVA for retinal diseases, announced Greg DiPasquale as Chief Commercial Officer.
- RTTNews · Sep 10, 10:39 AM EDTOutlook Therapeutics Highlights LYTENAVA FDA Approval And U.S. Commercial Opportunity(RTTNews) – Outlook Therapeutics, Inc. (OTLK), a biopharmaceutical company focused on retinal diseases, announced that Chief Executive Officer Bob Jahr participated in a Virtual Investor CEO Connect segment discussing the FDA approval of LYTENAVA and the company's plans for its U
- RTTNews · Aug 29, 6:34 AM EDTWhy Now On-Demand Conference Spotlights Nine Emerging Biotech And Healthcare Stories(RTTNews) – The Virtual Investor "Why Now" On-Demand Conference, hosted by Virtual Investor Co. in partnership with JTC Team, wrapped up on August 27, 2026. The program is designed to give investors and analysts direct access to management teams, each presenting why now is the ri
- RTTNews · Aug 28, 2:05 AM EDTOutlook Therapeutics Appoints Kevin Lundquist As CFO Ahead Of U.S. LYTENAVA Launch; Stock Up(RTTNews) – Outlook Therapeutics, Inc. (OTLK), a biopharmaceutical company that focuses on the treatment of retinal diseases, announced the appointment of Kevin Lundquist as Chief Financial Officer, effective September 1, 2026, succeeding Lawrence Kenyon.
- BNK Invest · Aug 17, 10:45 AM EDTMonday 8/17 Insider Buying Report: OTLK, MTDRAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at two noteworthy recent insider buys. At Outlook Therapeutics, a filing with the SEC revealed that on Wednesday, Ghiath
- Zacks · Aug 17, 10:00 AM EDTOTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales RampOutlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement.
- MarketBeat · Aug 14, 11:04 AM EDTOncobiologics Q3 Earnings Call Highlights3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices Oncobiologics (NASDAQ:OTLK) said it is preparing for the U.S. commercial launch of LYTENAVA after the Food and Drug Administration approved the product as the only FDA-approved ophthalmic formulation of bevacizumab fo
- RTTNews · Aug 14, 10:42 AM EDTOutlook Therapeutics Reports Q3 Net Loss; Advances U.S. Launch Of LYTENAVA(RTTNews) – Outlook Therapeutics, Inc. (OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA or bevacizumab-vikg, bevacizumab gamma for retinal diseases, reported financial results for the third quarter and provided a business update hig
- Zacks · Aug 14, 8:25 AM EDTOutlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue EstimatesOutlook Therapeutics, Inc. (OTLK) delivered earnings and revenue surprises of 0.00% and -99.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- NASDAQ.com · Aug 13, 4:00 PM EDTPre-Market Earnings Report for August 14, 2026 : USAS, SGML, OTLK, STRR, PAVM, LFWD, CMCT, QNRX, ACXPThe following companies are expected to report earnings prior to market open on 08/14/2026. Visit our Earnings Calendar for a full list of expected earnings releases.Americas Gold and Silver Corporation (USAS)is reporting for the quarter ending June 30, 2026. The consensus earni
- Zacks · Aug 13, 7:35 AM EDTZealand Pharma A/S (ZLDPF) Surpasses Q2 Earnings and Revenue EstimatesZealand Pharma AS (ZLDPF) delivered earnings and revenue surprises of +2,150.00% and +756.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Aug 13, 3:37 AM EDTOutlook Therapeutics Prices $55 Mln Offering To Support LYTENAVA Launch; Stock Down(RTTNews) – Outlook Therapeutics, Inc. (OTLK), a biopharmaceutical company, priced a public offering of 55.56 million shares and accompanying warrants to purchase up to 55.56 million shares at a combined public offering price of $0.99 for each share of common stock and accompanyi
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Outlook Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.